A. Stoop

发表

High-density mutagenesis by combined DNA shuffling and phage display to assign essential amino acid residues in protein-protein interactions: application to study structure-function of plasminogen activation inhibitor 1 (PAI-I).

I. Lasters, L. Jespers, H. Pannekoek, 2000, Journal of molecular biology.

The Composition of Complexes between Plasminogen Activator Inhibitor 1, Vitronectin and either Thrombin or Tissue-type Plasminogen Activator

K. Preissner, A. V. van Zonneveld, H. Pannekoek, 1997, Thrombosis and Haemostasis.

Different structural requirements for plasminogen activator inhibitor 1 (PAI-1) during latency transition and proteinase inhibition as evidenced by phage-displayed hypermutated PAI-1 libraries.

R. Read, T. Dafforn, H. Pannekoek, 2001, Journal of molecular biology.

Plasminogen activation independent of uPA and tPA maintains wound healing in gene‐deficient mice

B. Nielsen, K. Almholt, C. Craik, 2006, The EMBO journal.

Selective blockade of tumor necrosis factor receptor I inhibits proinflammatory cytokine and chemokine production in human rheumatoid arthritis synovial membrane cell cultures.

M. Feldmann, F. Brennan, A. Stoop, 2013, Arthritis and rheumatism.

Potential Regulatory Mechanism of Thrombin Activity by PAI-1 / Vitronectin Complexes Colocalization of Thrombin , PAI-1 , and Vitronectin in the Atherosclerotic Vessel Wall : A

F. Lupu, H. Pannekoek, A. Stoop, 2000 .

M. Feldmann, A. Stoop, Emily M. Schmidt, 2014 .

Selective Tumor Necrosis Factor Receptor I Blockade Is Antiinflammatory and Reveals Immunoregulatory Role of Tumor Necrosis Factor Receptor II in Collagen‐Induced Arthritis

M. Feldmann, J. Dean, K. Blazek, 2014, Arthritis & rheumatology.

Selective inhibition of TNFR1 reduces osteoclast numbers and is differentiated from anti-TNF in a LPS-driven model of inflammatory bone loss.

M. Feldmann, A. I. Espírito Santo, N. Horwood, 2015, Biochemical and biophysical research communications.

TNFR2 increases the sensitivity of ligand-induced activation of the p38 MAPK and NF-κB pathways and signals TRAF2 protein degradation in macrophages.

M. Feldmann, J. Dean, Richard O. Williams, 2014, Cellular signalling.

Tumour necrosis factor receptor I blockade shows that TNF‐dependent and TNF‐independent mechanisms synergise in TNF receptor associated periodic syndrome

P. Tighe, O. Negm, L. Fairclough, 2015, European journal of immunology.

Molecular advances in plasminogen activator inhibitor 1 interaction with thrombin and tissue-type plasminogen activator.

A. Horrevoets, H. Pannekoek, M. van Meijer, 1997, Trends in cardiovascular medicine.

Engineering of a macromolecular scaffold to develop specific protease inhibitors

C. Craik, A. Stoop, C. Craik, 2003, Nature Biotechnology.

Colocalization of thrombin, PAI-1, and vitronectin in the atherosclerotic vessel wall: A potential regulatory mechanism of thrombin activity by PAI-1/vitronectin complexes.

F. Lupu, H. Pannekoek, A. Stoop, 2000, Arteriosclerosis, thrombosis, and vascular biology.

Analysis of an engineered plasma kallikrein inhibitor and its effect on contact activation

C. Craik, A. Stoop, C. Eggers, 2010, Biological chemistry.

The variable region-1 from tissue-type plasminogen activator confers specificity for plasminogen activator inhibitor-1 to thrombin by facilitating catalysis: release of a kinetic block by a heterologous protein surface loop.

W. Bode, R. Dekker, A. Horrevoets, 1999, Journal of molecular biology.

Pharmacokinetic and Pharmacodynamic Characterisation of an Anti-Mouse TNF Receptor 1 Domain Antibody Formatted for In Vivo Half-Life Extension

A. Stoop, A. Sanderson, M. Ovečka, 2015, PloS one.